Product Description
Mechanisms of Action: Cell Therapy
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Instil Bio
Company Location: DALLAS TX 75219
Company CEO: Bronson Crouch
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Non-Small-Cell Lung Cancer|Ovarian Cancer|Renal Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ITIL-306-201 | P1 |
Active, not recruiting |
Renal Cell Carcinoma|Ovarian Cancer|Non-Small-Cell Lung Cancer |
2025-07-01 |
44% |